Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. (SUPN) for potential violations of federal securities laws following the failure of its Phase 2b study of SPN-820 for treatment-resistant depression.
March 14, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after its Phase 2b study of SPN-820 failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, potentially affecting its stock price negatively. The investigation by Levi & Korsinsky adds legal uncertainty, which could further impact investor confidence and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100